Biopharma | November 28, 2025
Exyte completes Pharmaplan integration
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
A key highlight will be Brenntag’s qualified amino acids portfolio
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Subscribe To Our Newsletter & Stay Updated
